세계의 리포솜 독소루비신 시장 보고서(2025년)

Liposomal doxorubicin is a form of the chemotherapy drug doxorubicin enclosed within lipid bilayers, forming tiny vesicles known as liposomes. This encapsulation modifies how the drug moves through the body, leading to longer circulation in the bloodstream and increased accumulation at tumor sites due to improved permeability and retention effects. Liposomal doxorubicin is employed in treating different cancers such as ovarian cancer, breast cancer, and Kaposi's sarcoma, potentially reducing the risk of heart-related side effects compared to traditional doxorubicin formulations.

The primary types of liposomal doxorubicin include Doxil or Caelyx, Lipodox, Myocet, and others. Doxil, also marketed as Caelyx, is a specific brand of liposomal doxorubicin used in chemotherapy for various cancer types. It is administered via injection and is applied in treating leukemia, bone sarcoma, breast cancer, endometrial cancer, kidney cancer, multiple myeloma, Kaposi sarcoma, among others. It is utilized by various end-users including hospitals, home care settings, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The liposomal doxorubicin market research report is one of a series of new reports from The Business Research Company that provides liposomal doxorubicin market statistics, including liposomal doxorubicin industry global market size, regional shares, competitors with a liposomal doxorubicin market share, detailed liposomal doxorubicin market segments, market trends and opportunities, and any further data you may need to thrive in the liposomal doxorubicin industry. This liposomal doxorubicin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The liposomal doxorubicin market size has grown strongly in recent years. It will grow from $1.23 billion in 2024 to $1.32 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to improved liposome formulations, favorable reimbursement policies for cancer treatments, growing awareness about the importance of cancer screening programs, enhanced healthcare infrastructure, and increasing patient preference for minimally invasive cancer treatments.

The liposomal doxorubicin market size is expected to see strong growth in the next few years. It will grow to $1.69 billion in 2029 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to rising awareness about cancer treatment options, increasing clinical trials, increasing adoption of combination therapies, rising healthcare expenditure, and growing preference for targeted therapies. Major trends in the forecast period include the integration of artificial intelligence (AI) and machine learning algorithms to facilitate drug discovery, utilizing 3D printing technologies, magnetic targeting methods, innovative strategies such as tumor-penetrating peptides or ultrasound-mediated drug delivery, and advancements in drug delivery technology.

The forecast of 6.3% growth over the next five years reflects a modest reduction of 0.5% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. cancer treatment protocols by inflating prices of nanoparticle chemotherapeutics and stability testing equipment developed in Germany and Belgium, resulting in reduced treatment options and higher oncology pharmacy expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of cancer is expected to drive the growth of the liposomal doxorubicin market in the coming years. Cancer is a group of diseases that can occur in almost any organ or tissue, caused by abnormal cell growth that spreads beyond its normal boundaries, invading other organs or neighboring body parts. The rise in cancer cases can be attributed to factors such as an aging population, lifestyle changes, environmental exposures, and advancements in diagnostic methods. Liposomal doxorubicin is used in cancer therapy to improve drug delivery to tumors, minimize toxicity, and enhance treatment outcomes. For example, in January 2024, the American Cancer Society, a U.S.-based nonprofit organization, reported an increase in cancer cases to 2,001,140 in 2024, up from 1,958,310 in 2023, reflecting a growth rate of 2.19%. As a result, the growing prevalence of cancer is fueling the growth of the liposomal doxorubicin market.

Key players in the liposomal doxorubicin market are concentrating on advancing drug delivery systems such as PEGylated liposomes to enhance the pharmacokinetics and distribution of doxorubicin, thereby improving patient outcomes. These innovations ensure drugs are targeted more effectively to cancer cells while reducing side effects. For instance, in May 2022, Accord Healthcare Limited introduced Zolsketil, a pegylated liposomal 2mg/ml concentrate for infusion dispersion, as a generic alternative to doxorubicin, a widely used cancer treatment.

In January 2024, CHEPLAPHARM Arzneimittel GmbH, a Germany-based pharmaceutical company, acquired the European rights to Myocet from Teva Pharmaceutical Industries Ltd. for an undisclosed amount. This acquisition strengthens CHEPLAPHARM's oncology portfolio by adding Myocet, a non-pegylated liposomal doxorubicin formulation, in line with its strategy to incorporate well-established drugs. Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical company, offers the liposomal doxorubicin formulation Myocet.

Major companies operating in the liposomal doxorubicin market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., AstraZeneca plc, Takeda Pharmaceutical Company, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd, Baxter International Inc., Astellas Pharma, Sun Pharmaceutical Industries Ltd, Jazz Pharmaceuticals, Cipla Inc., Endo Pharmaceuticals, Lupin Limited, Mallinckrodt Pharmaceuticals, Zydus Cadila, Accord Healthcare Limited, Shanghai Fudan-zhangjiang Bio-Pharmaceutical Co.Ltd, TTY Biopharm Company Limited, SRS Life Sciences

North America was the largest region in the liposomal doxorubicin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the liposomal doxorubicin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the liposomal doxorubicin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The liposomal doxorubicin market consists of sales of Doxil and Lipodox. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Liposomal Doxorubicin Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on liposomal doxorubicin market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for liposomal doxorubicin ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The liposomal doxorubicin market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Doxil Or Caelyx; Lipodox; Myocet; Other Products
• 2) By Route Of Administration: Parenteral; Other Routes Of Administration
• 3) By Application: Leukemia; Bone Sarcoma; Breast Cancer; Endometrial Cancer; Kidney Cancer; Multiple Myeloma; Kaposi Sarcoma; Other Applications
• 4) By End-Users: Hospitals; Homecare; Other End-Users
• Subsegments:
• 1) By Doxil Or Caelyx: Different Dosage Strengths; Branded Versions; Generic Versions
• 2) By Lipodox: Different Dosage Strengths; Branded Versions; Generic Versions
• 3) By Myocet: Different Dosage Strengths; Branded Versions; Generic Versions
• 4) By Other Products: Newer Liposomal Formulations; Regional Brand Variants; Combination Therapies
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; AbbVie Inc.; AstraZeneca plc; Takeda Pharmaceutical Company; Eli Lilly and Company; Amgen Inc.; Teva Pharmaceutical Industries Ltd; Baxter International Inc.; Astellas Pharma; Sun Pharmaceutical Industries Ltd; Jazz Pharmaceuticals; Cipla Inc.; Endo Pharmaceuticals; Lupin Limited; Mallinckrodt Pharmaceuticals; Zydus Cadila; Accord Healthcare Limited; Shanghai Fudan-zhangjiang Bio-Pharmaceutical Co.Ltd; TTY Biopharm Company Limited; SRS Life Sciences
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Liposomal Doxorubicin Market Characteristics

3. Liposomal Doxorubicin Market Trends And Strategies

4. Liposomal Doxorubicin Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Liposomal Doxorubicin Growth Analysis And Strategic Analysis Framework

• 5.1. Global Liposomal Doxorubicin PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Liposomal Doxorubicin Market Growth Rate Analysis
• 5.4. Global Liposomal Doxorubicin Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Liposomal Doxorubicin Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Liposomal Doxorubicin Total Addressable Market (TAM)

6. Liposomal Doxorubicin Market Segmentation

• 6.1. Global Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Doxil Or Caelyx
• Lipodox
• Myocet
• Other Products
• 6.2. Global Liposomal Doxorubicin Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Parenteral
• Other Routes Of Administration
• 6.3. Global Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Leukemia
• Bone Sarcoma
• Breast Cancer
• Endometrial Cancer
• Kidney Cancer
• Multiple Myeloma
• Kaposi Sarcoma
• Other Applications
• 6.4. Global Liposomal Doxorubicin Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Other End-Users
• 6.5. Global Liposomal Doxorubicin Market, Sub-Segmentation Of Doxil Or Caelyx, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Different Dosage Strengths
• Branded Versions
• Generic Versions
• 6.6. Global Liposomal Doxorubicin Market, Sub-Segmentation Of Lipodox, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Different Dosage Strengths
• Branded Versions
• Generic Versions
• 6.7. Global Liposomal Doxorubicin Market, Sub-Segmentation Of Myocet, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Different Dosage Strengths
• Branded Versions
• Generic Versions
• 6.8. Global Liposomal Doxorubicin Market, Sub-Segmentation Of Other Products, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Newer Liposomal Formulations
• Regional Brand Variants
• Combination Therapies

7. Liposomal Doxorubicin Market Regional And Country Analysis

• 7.1. Global Liposomal Doxorubicin Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Liposomal Doxorubicin Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Liposomal Doxorubicin Market

• 8.1. Asia-Pacific Liposomal Doxorubicin Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Liposomal Doxorubicin Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Liposomal Doxorubicin Market

• 9.1. China Liposomal Doxorubicin Market Overview
• 9.2. China Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Liposomal Doxorubicin Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Liposomal Doxorubicin Market

• 10.1. India Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Liposomal Doxorubicin Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Liposomal Doxorubicin Market

• 11.1. Japan Liposomal Doxorubicin Market Overview
• 11.2. Japan Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Liposomal Doxorubicin Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Liposomal Doxorubicin Market

• 12.1. Australia Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Liposomal Doxorubicin Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Liposomal Doxorubicin Market

• 13.1. Indonesia Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Liposomal Doxorubicin Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Liposomal Doxorubicin Market

• 14.1. South Korea Liposomal Doxorubicin Market Overview
• 14.2. South Korea Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Liposomal Doxorubicin Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Liposomal Doxorubicin Market

• 15.1. Western Europe Liposomal Doxorubicin Market Overview
• 15.2. Western Europe Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Liposomal Doxorubicin Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Liposomal Doxorubicin Market

• 16.1. UK Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Liposomal Doxorubicin Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Liposomal Doxorubicin Market

• 17.1. Germany Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Liposomal Doxorubicin Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Liposomal Doxorubicin Market

• 18.1. France Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Liposomal Doxorubicin Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Liposomal Doxorubicin Market

• 19.1. Italy Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Liposomal Doxorubicin Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Liposomal Doxorubicin Market

• 20.1. Spain Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Liposomal Doxorubicin Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Liposomal Doxorubicin Market

• 21.1. Eastern Europe Liposomal Doxorubicin Market Overview
• 21.2. Eastern Europe Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Liposomal Doxorubicin Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Liposomal Doxorubicin Market

• 22.1. Russia Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Liposomal Doxorubicin Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Liposomal Doxorubicin Market

• 23.1. North America Liposomal Doxorubicin Market Overview
• 23.2. North America Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Liposomal Doxorubicin Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Liposomal Doxorubicin Market

• 24.1. USA Liposomal Doxorubicin Market Overview
• 24.2. USA Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Liposomal Doxorubicin Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Liposomal Doxorubicin Market

• 25.1. Canada Liposomal Doxorubicin Market Overview
• 25.2. Canada Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Liposomal Doxorubicin Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Liposomal Doxorubicin Market

• 26.1. South America Liposomal Doxorubicin Market Overview
• 26.2. South America Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Liposomal Doxorubicin Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Liposomal Doxorubicin Market

• 27.1. Brazil Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Liposomal Doxorubicin Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Liposomal Doxorubicin Market

• 28.1. Middle East Liposomal Doxorubicin Market Overview
• 28.2. Middle East Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Liposomal Doxorubicin Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Liposomal Doxorubicin Market

• 29.1. Africa Liposomal Doxorubicin Market Overview
• 29.2. Africa Liposomal Doxorubicin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Liposomal Doxorubicin Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Liposomal Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Liposomal Doxorubicin Market Competitive Landscape And Company Profiles

• 30.1. Liposomal Doxorubicin Market Competitive Landscape
• 30.2. Liposomal Doxorubicin Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Takeda Pharmaceutical Company Overview, Products and Services, Strategy and Financial Analysis

31. Liposomal Doxorubicin Market Other Major And Innovative Companies

• 31.1. Eli Lilly and Company
• 31.2. Amgen Inc.
• 31.3. Teva Pharmaceutical Industries Ltd
• 31.4. Baxter International Inc.
• 31.5. Astellas Pharma
• 31.6. Sun Pharmaceutical Industries Ltd
• 31.7. Jazz Pharmaceuticals
• 31.8. Cipla Inc.
• 31.9. Endo Pharmaceuticals
• 31.10. Lupin Limited
• 31.11. Mallinckrodt Pharmaceuticals
• 31.12. Zydus Cadila
• 31.13. Accord Healthcare Limited
• 31.14. Shanghai Fudan-zhangjiang Bio-Pharmaceutical Co.Ltd
• 31.15. TTY Biopharm Company Limited

32. Global Liposomal Doxorubicin Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Liposomal Doxorubicin Market

34. Recent Developments In The Liposomal Doxorubicin Market

35. Liposomal Doxorubicin Market High Potential Countries, Segments and Strategies

• 35.1 Liposomal Doxorubicin Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Liposomal Doxorubicin Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Liposomal Doxorubicin Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer